| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Institute for Cardiovascular Research, VU University Medical Center, Laboratory for Physiology and Intensive Care Unit, Amsterdam, The Netherlands
* To whom correspondence should be addressed. E-mail: amg.versteilen{at}vumc.nl.
Renal ischemia-reperfusion (I/R) results in vascular dysfunction characterized by a reduced endothelium-dependent vasodilatation and subsequently impaired blood flow. In this study we investigated the role of Rho kinase in eNOS mediated regulation of renal blood flow and vasomotor tone in renal I/R. Male Wistar rats were subjected to 60 minutes bilateral clamping of the renal arteries or sham procedure. One hour before clamping, the Rho kinase inhibitor Y27632 (1 mg/kg) was intravenously infused. After I/R renal blood flow was measured using fluorescent microspheres. I/R resulted in a 62% decrease in renal blood flow. In contrast, the blood flow decrease in the group treated with the Rho kinase inhibitor (YI/R) was prevented. Endothelium-dependent vasodilatation of renal arcuate arteries to acetylcholine (Ach) was measured ex vivo in a pressure myograph. These experiments demonstrated that the in vivo treatment with the Rho kinase inhibitor prevented the decrease in NO-mediated vasodilator response. In addition, after I/R renal interlobar arteries showed a decrease in phosphorylated eNOS and vasodilator-stimulated phosphoprotein (VASP), a marker for bioactive NO, which was attenuated by in vivo Rho kinase inhibition. These findings indicate that in vivo inhibition of Rho kinase in renal I/R preserves renal blood flow by improving eNOS function.
This article has been cited by other articles:
|
|
 |
|
  K. T. B. Mouchaers, I. Schalij, A. M. G. Versteilen, A. M. Hadi, G. P. van Nieuw Amerongen, V. W. M. van Hinsbergh, P. E. Postmus, W. J. van der Laarse, and A. Vonk-Noordegraaf Endothelin receptor blockade combined with phosphodiesterase-5 inhibition increases right ventricular mitochondrial capacity in pulmonary arterial hypertension Am J Physiol Heart Circ Physiol, July 1, 2009; 297(1): H200 - H207. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Prakash, M. H. de Borst, M. Lacombe, F. Opdam, P. A. Klok, H. van Goor, D. K.F. Meijer, F. Moolenaar, K. Poelstra, and R. J. Kok Inhibition of Renal Rho Kinase Attenuates Ischemia/Reperfusion-Induced Injury J. Am. Soc. Nephrol., November 1, 2008; 19(11): 2086 - 2097. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. P. van Nieuw Amerongen, R. J. P. Musters, E. C. Eringa, P. Sipkema, and V. W. M. van Hinsbergh Thrombin-induced endothelial barrier disruption in intact microvessels: role of RhoA/Rho kinase-myosin phosphatase axis Am J Physiol Cell Physiol, May 1, 2008; 294(5): C1234 - C1241. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Mejia-Vilet, V. Ramirez, C. Cruz, N. Uribe, G. Gamba, and N. A. Bobadilla Renal ischemia-reperfusion injury is prevented by the mineralocorticoid receptor blocker spironolactone Am J Physiol Renal Physiol, July 1, 2007; 293(1): F78 - F86. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| Visit Other APS Journals Online |
